Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Preparation and Characterization of Four Major Novel Degradation Products of Pralatrexate Injection and Validation of HPLC-UV Method

Author(s): Regella Venkata Rama Prabhakara Sastry*, Chidambaram Subramanian Venkatesan, Bhetanabhotla Sarveswara Sastry, Singaram Sathiyanarayanan and Sanapati Murali

Volume 15, Issue 7, 2019

Page: [724 - 737] Pages: 14

DOI: 10.2174/1573412914666180910120547

Price: $65

Abstract

Background: Four major degradation products (1-4) of pralatrexate injection were formed under hydrolytic and light stress conditions. The impurities 1 and 2 were the potential photo degradation products and the impurities 3 and 4 were the potential hydrolytic degradation products.

Objective: To prepare and characterize the novel degradation impurities 1, 2, 3 and 4 of pralatrexate injection using NMR, HR MS and IR techniques; and to develop and validate stability indicating analytical reverse phase HPLC-UV method for quantitative simultaneous determination of potential degradation impurities, related substances of pralatrexate and pralatrexate active in pralatrexate liquid formulation.

Methods: Gradient HPLC-UV method was developed for the quantification of degradation impurities, related substances and pralatrexate in pralatrexate injection. The separation was achieved on C18 column (250 mm X 4.6 mm, 5µm) using a mobile phase composed of sodium dihydrogen phosphate monohydrate in water (pH 3.0; 0.01M) and methanol. The components were monitored by the UVvisible detector at 242 nm with a flow rate of 1.0 mL/min.

Results: The method validation parameters such as accuracy, selectivity, linearity, LOD, LOQ, precision, ruggedness and robustness were demonstrated successfully for pralatrexate and its degradation impurities. The stability-indicating capability of the developed HPLC method was demonstrated by adequate separation of all potential pralatrexate related substances from pralatrexate stressed drug product samples.

Conclusion: The developed stability indicating HPLC method was found to be suitable for the simultaneous quantitative determination of potential degradation impurities and related substances of pralatrexate and pralatrexate active in pralatrexate liquid formulation.

Keywords: Pralatrexate, stress conditions, degradation products, gradient HPLC-UV, validation, stability-indicating method.

« Previous Next »
Graphical Abstract

[1]
Department of Health and Ageing. Therapeutic Goods and Administration: Australian Public Assessment Report for Pralatrexate 2013.
[2]
Liu, C.; Yang, C.; Lu, L.; Wang, W.; Tan, W.; Leung, C.H.; Ma, D.L. Luminescent iridium(III) complexes as COX-2-specific imaging agents in cancer cells. Chem. Commun. , 2017, 53, 2822-2825.
[3]
Lin, S.; Lu, L.; Kang, T.; Mergny, J.L.; Leung, C.H.; Ma, D.L. Interaction of an Iridium (III) Complex with G-Quadruplex DNA and its application in luminescent switch- on detection of Siglec-5. Anal. Chem., 2016, 88, 10290-10295.
[4]
Wang, W.; Vellaisamy, K.; Li, G.; Wu, C.; Ko, C.N.; Leung, C.H.; Ma, D.L. Development of a long-lived luminescence probe for visualizing β-Galactosidase in ovarian carcinoma cells. Anal. Chem., 2017, 89, 11679-11684.
[5]
Hori, Y.; Otomura, N.; Nishida, A.; Nishiura, M.; Umeno, M.; Suetake, I.; Kikuchi, K. Synthetic-molecule/protein hybrid probe with fluorogenic switch for live - cell imaging of dna methylation. J. Am. Chem. Soc., 2018, 140, 1686-1690.
[6]
Nicholas, W.; Davis, III P.J.; Yu, Z.; Chan, J. NitroxyFluor: A thiol-based fluorescent probe for live-cell imaging of nitroxyl. J. Am. Chem. Soc., 2017, 139, 18476-18479.
[7]
Wu, C.; Vellaisamy, K.; Yang, G.; Dong, Z.Z.; Leung, C.H.; Liu, J.B.; Ma, D-K. A reaction-based luminescent switch-on sensor for the detection of OH- ions in simulated waste water. Dalton Trans., 2017, 46, 6677-6682.
[8]
Yadav, N.; Singh, P.; Mehrotra, R. Evaluation of stability of 5- fluorouracil under different stress conditions: high performance liquid chromatography and infrared spectroscopic approach. Curr. Pharm. Anal., 2012, 8, 49-55.
[9]
Hanif, M.; Akhtar, M.F.; Naeem, S.; Wahid, M.; Shehzad, M.A.; Saadullah, M.; Nasir, B.; Afzal, S. Development and validation of a new hplc method for the detection of 5-fluorouracil in mobile phase and in plasma. Curr. Pharm. Anal., 2018, 14, 3-7.
[10]
He, W.; Jennifer, H.; Martin, P.N.; Lu, S.W.; Euan, T.; Walpole, G.D. A simple and sensitive LC-MS/MS method for the simultaneous determination of cyclophosphamide and doxorubicin concentrations in human plasma. Curr. Pharm. Anal., 2018, 14, 53-59.
[11]
ICH Q 6A(R2), Test procedures and acceptance criteria for new drug substances and new drug products: chemical substances (step4), in: International Conference on Harmonization, Geneva,, 2006.
[12]
ICH Q3B(R2), Impurities in new drug products (step4), in: International Conference on Harmonization, Geneva,, 2006.
[13]
Kulsum, S.; Sagar, G.V. Validated RP-HPLC method for the determination of pralatrexate in bulk and pharmaceutical dosage forms. World J. Pharm. Pharm. Sci., 2015, 5, 1173-1171.
[14]
Sastry, R.V.R.P.; Venkatesan, C.S.; Sastry, B.S.; Mahesh, K. Identification and characterization of forced degradation products of pralatrexate injection by LC-PDA and LC-MS. J. Pharm. Biomed. Anal., 2016, 131, 400-409.
[15]
Chatterji, D.; Gallelli, J.F. Thermal and photolytic decomposition of methotrexate in aqueous solutions. J. Pharm. Sci., 1978, 67, 526-531.
[16]
Gupta, A.; Ahmad, W.; Iqbal, J.; Zaheer, M.R. Photochemical electron transfer reactions of talotrexin. Int. J. Phar. Res., 2016, 7, 190-195.
[17]
Sato, N.; Saito, N. Studies on pyrazines. 17. [1]. An efficient synthesis of pteridine-6-carboxylic acids. J. Heterocycl. Chem., 1988, 25, 1737.
[18]
Dion, R.L.; Loo, T.L. The oxidation of certain pteroylglutamic acid analogs. J. Org. Chem., 1961, 26(6), 1857-1859.
[19]
DailyMed-FOLOTYN- pralatrexate injection, Allos Therapeutics. 2016.
[20]
ICH Q1A (R2), Stability testing of new drug substances and products (STEP4), in: International Conference on Harmonization, Geneva,, 1996.
[21]
ICH Q1B, Stability testing: photo stability testing of new drug substances and products (step4), in: International Conference on Harmonization, Geneva,, 1996.
[22]
ICH Q2 (R1) Validation of analytical procedures: Text and Methodology (STEP4), in: International Conference on Harmonization, Geneva1996.
[23]
Center for Drug Evaluation and Research (CDER), Reviewer Guidance, Validation of Chromatographic Methods 1994.

Rights & Permissions Print Cite
Article Metrics
38
2
1
1
© 2024 Bentham Science Publishers | Privacy Policy